Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070261 | 0.86 | MEN1 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2OPRK1 | |
| SCHEMBL11102216 | 0.83 | MEN1 (0.59) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL178869 | 0.82 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL178870 | 0.82 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL10070262 | 0.80 | MEN1 (0.53) | MEN1KMT2ABCHE | |
| SCHEMBL10070264 | 0.79 | BCHE (0.58) | MEN1KMT2AKDM4EALDH1A1BCHE | |
| SCHEMBL10070263 | 0.79 | BCHE (0.58) | MEN1KMT2AKDM4EALDH1A1BCHE | |
| SCHEMBL178867 | 0.79 | — | — | |
| SCHEMBL11098569 | 0.78 | OPRK1 (0.54) | MEN1KMT2AALDH1A1SMN1; SMN2OPRK1 | |
| SCHEMBL27633641 | 0.76 | MEN1 (0.69) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MEN1 4664/4885KMT2A 2778/4885KDM4E 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.